Frontiers in Genetics (Aug 2022)

Multi-omics analysis reveals prognostic and therapeutic value of cuproptosis-related lncRNAs in oral squamous cell carcinoma

  • Xiaoguang Li,
  • Wenbin Zhou,
  • Wenbin Zhou,
  • Wenbin Zhou,
  • Chang Zhu,
  • Chang Zhu,
  • Chang Zhu,
  • Jiechen Liu,
  • Jiechen Liu,
  • Jiechen Liu,
  • Zedong Ming,
  • Zedong Ming,
  • Zedong Ming,
  • Cong Ma,
  • Cong Ma,
  • Cong Ma,
  • Qing Li,
  • Qing Li,
  • Qing Li

DOI
https://doi.org/10.3389/fgene.2022.984911
Journal volume & issue
Vol. 13

Abstract

Read online

Background: Extensive research revealed copper and lncRNA can regulate tumor progression. Additionally, cuproptosis has been proven can cause cell death that may affect the development of tumor. However, there is little research focused on the potential prognostic and therapeutic role of cuproptosis-related lncRNA in OSCC patients.Methods: Data used were for bioinformatics analyses were downloaded from both the TCGA database and GEO database. The R software were used for statistical analysis. Mapping was done using the tool of FigureYa.Results: The signature consist of 7 cuproptosis-related lncRNA was identified through lasso and Cox regression analysis and a nomogram was developed. In addition, we performed genomic analyses including pathway enrichment analysis and mutation analysis between two groups. It was found that OSCC patients were prone to TP53, TTN, FAT1 and NOTCH1 mutations and a difference of mutation analysis between the two groups was significant. Results of TIDE analysis indicating that patients in low risk group were more susceptible to immunotherapy. Accordingly, results of subclass mapping analysis confirmed our findings, which revealed that patients with low riskscore were more likely to respond to immunotherapy.Conclusion: We have successfully identified and validated a novel prognostic signature with a strong independent predictive capacity. And we have found that patients with low riskscore were more susceptible to immunotherapy, especially PD-1 inhibitor therapy.

Keywords